Corporate News

Grant of Share Options and PDMR dealing

17 September 2021

GENinCode Plc (AIM:GENI), Oxford, UK, the cardiovascular disease company focused on predictive genetics for the prevention of cardiovascular disease, announces today that the Remuneration Committee has recommended, and the Board has approved, to issue options over a total of 572,000 ordinary shares of £0.01 each in the capital of the Company (“Share Options”).

The Share Options have been issued in line with the Company’s existing share option plan to Paul Foulger, a director of the Company. The Share Options have been issued in addition to the existing options over ordinary shares granted to Paul Foulger on 15 April 2021 and combined, the number of ordinary shares held under option by Paul Foulger is 1,144,000, representing 1.19% of the existing issued ordinary share capital of the Company.

The Share Options are exercisable once the average market value of the Company’s shares for a period of 30 consecutive dealing days following the date of the issue of the Share Options first exceeds two times the exercise price of £0.44.



GENinCode plc
Matthew Walls, CEO Via Walbrook PR
Paul Foulger, CFO  
Stifel Nicolaus Europe Limited (Nomad and Joint Broker) Tel: +44 (0)20 7710 7600
Alex Price / Ben Maddison / Richard Short  
Cenkos Securities Plc (Joint Broker) Tel: +44 (0)20 7397 8900
Giles Balleny  
Dale Bellis / Michael Johnson (Sales)        
Walbrook PR Limited Tel: 020 7933 8780 or [email protected]
Anna Dunphy / Paul McManus / Louis Ashe-Jepson  


About GENinCode plc

GENinCode plc (AIM: GENI) is engaged in the risk assessment, prediction and prevention of cardiovascular disease (“CVD”). CVD is the leading cause of death worldwide accounting for approximately 18 million deaths annually. The Company’s products and technology have been developed with the aim of predicting the onset of CVD and providing a personalised treatment pathway for patient management. Its products have been the subject of clinical studies on over 75,000 patients to assess and predict the onset of CVD.

The Company was incorporated in September 2018 to acquire the assets, intellectual property and know-how of the Ferrer inCode and Gendiag.exe businesses, which were then part of Grupo Ferrer Internacional S.A., a large Spanish multinational private pharmaceutical and healthcare company. The technology and products acquired included Cardio inCode®, Lipid inCode®, Thrombo inCode® and Sudd inCode®. The Directors believe that approximately €50 million has been invested in the research and development of these products since 2007. The Company has begun to commercialise these products in Europe and is now targeting the UK and US.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:


1 Details of the person discharging managerial responsibilities/person closely associated
a) Name Paul Foulger
2 Reason for the notification
a) Position/status CFO
b) Initial notification/ Amendment Initial Notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name GENinCode Plc
b) LEI 213800UX6TE7K65O2892
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument 
Identification code
Ordinary Shares of £0.01p
b) Nature of the transaction Grant of conditional shares in the Company's Share Option Scheme
c) Price(s) and volume(s)
Exercise Price Volume
 £0.44 572,000
d) Aggregated information
 - Aggregated volume
 - Price
N/A - single transaction
e) Date of the transaction  17 September 2021
f) Place of the transaction  Outside a trading venue